Abbott India warns of potential laxative syrup shortages amid production halt
foxbusiness.comCheck out what's clicking on FoxBusiness.com
Abbott Laboratories' Indian unit has warned of potential supply shortages of two popular laxative syrups after production was prohibited in India's Goa state, where drug inspectors have found lapses at a company factory, a letter shows.
Goa, where Abbott has one of its two India plants, asked the company to halt production of Cremaffin and Duphalac syrups last month. The request followed the recall of another Abbott drug which triggered factory inspections by health officials who found contamination risks and sanitisation issues.
The two laxative brands together have estimated annual sales of $70 million in India, healthcare data firm Pharmarack says.
In a letter to Goa's Directorate of Food and Drugs Administration dated Sept. 18, which is not public and has not previously been reported on, Abbott pushed state regulators to allow it to restart manufacturing the two medicines.
«The two products have a high consumption rate and are highly prescribed,» Abbott said in the letter seen by Reuters. «We are likely to face a supply shortage of these two products,» it warned.
INDIA TELLS CITIZENS IN CANADA TO 'EXERCISE UTMOST CAUTION' IN DISPUTE OVER MURDERED SIKH ACTIVIST
Cremaffin, Abbott argued, is a «necessity to support hospitalised patients» while Duphalac is prescribed in serious disorders caused by liver failure.
Abbott in India and the Goa FDA spokesperson did not immediately respond to requests for comment.
India is a major market for Abbott. Its currently regulatory challenges in the country began in August with the recall of thousands of bottles of its popular Digene Gel antacid syrup following complaints about its taste and odour.
A worker waters plants next to an
Read more on foxbusiness.com
